Most medicines sold today are not made entirely inside the walls of the company whose name is on the box. Development, manufacturing, testing, and supply increasingly run through networks of external partners and as those networks grow larger and more complex, keeping quality consistent across them becomes a fundamentally different job from managing quality on your own factory floor.
That job has a name: External Quality.
External Quality sits at the intersection of Quality, External Manufacturing, CMC, Technical Operations, Supply Chain, Procurement, and CDMO management. Its role is not simply to check whether a contract development and manufacturing organization (CDMO) is compliant. It is to understand the quality risks across an external network, decide where oversight is needed, build the right governance, and establish relationships that surface problems before they become supply failures or regulatory findings.
The stakes are visible across the industry. Deviations, data-integrity concerns, weak investigations, and poor change control at external sites can ultimately hit a sponsor’s products, timelines, regulatory standing, and patients.
PharmaSource has covered many of these issues directly — through interviews on CDMO quality oversight, quality culture, supplier relationships, outsourcing, technology transfer, and external manufacturing. Pulled together, that reporting gives a practical picture of what strong External Quality management looks like today.
What Is External Quality?
External Quality is the discipline of managing and overseeing quality across an organization’s external manufacturing and supply network.
Depending on the company, the function may sit within External Manufacturing Quality, Supplier Quality, External Supply Quality, Quality Operations, or a broader Quality organization.
Its responsibilities can include:
- Evaluating and qualifying potential CDMO partners
- Performing quality due diligence
- Assessing regulatory inspection history
- Establishing quality agreements
- Defining quality responsibilities between sponsor and CDMO
- Setting risk-based oversight models
- Monitoring deviations, CAPAs, change controls, and complaints
- Reviewing quality metrics and trends
- Conducting audits and on-site assessments
- Supporting technology transfer and process validation
- Managing escalation and governance
- Preparing for regulatory inspections
- Assessing quality culture and organizational capability
- Using data to identify emerging quality risks
- Maintaining oversight throughout the product lifecycle
The function goes well beyond compliance monitoring. A useful way to think about External Quality is that it answers three questions:
Those questions need answers before a CDMO is selected, throughout the relationship, and as manufacturing activities evolve. PharmaSource’s Outsourcing Oversight Plan Template provides a practical framework for the governance and oversight activities required across an outsourced manufacturing relationship.
Why External Quality Has Become More Important
The pharmaceutical outsourcing model has changed significantly. Companies increasingly rely on networks of CDMOs across multiple geographies, manufacturing technologies, modalities, and stages of the product lifecycle. A single product may involve different external partners for drug substance, drug product, analytical testing, and packaging.
This creates a quality challenge: the sponsor remains accountable for the product even when most of the manufacturing activity happens outside its own facilities.
The consequences of weak external oversight can be significant. PharmaSource’s reporting on Regulatory Violations Are the #1 Reason CDMOs Lose Bids shows how regulatory findings can directly affect a CDMO’s ability to compete for outsourced manufacturing work.
For External Quality teams, this means qualification cannot be reduced to a single audit or questionnaire. Historical inspection findings, recurring deviations, CAPA effectiveness, change-control performance, data integrity, staffing, quality culture, management commitment, and transparency all provide information about the actual quality maturity of a potential partner.
As Firelli Alonso, former Senior Director of External Manufacturing at Pfizer, explained in PharmaSource’s discussion on CDMO selection:
“Quality is number one for anything.”— Firelli Alonso, former Senior Director of External Manufacturing, Pfizer
Her approach to evaluating potential CDMOs goes beyond reviewing documentation — she describes examining sterility issues, regulatory inspections, FDA 483 observations, and warning letters as part of understanding a prospective partner’s quality history. That principle is central to External Quality: quality should be assessed as a pattern of behavior and performance, not simply a collection of documents.
What Does an External Quality Team Actually Do?
1. CDMO Selection and Qualification
External Quality should be involved early. A CDMO may look attractive based on technical capabilities, capacity, geography, or price, but none of those answer the fundamental question: can the organization consistently manufacture the product to the required standard?
Quality due diligence should examine regulatory inspection history, warning letters, major and recurring deviations, CAPA effectiveness, change control performance, data integrity controls, batch release performance, contamination controls, validation maturity, staffing and turnover, quality culture, and previous experience with comparable products.
PharmaSource’s guide, Pharmaceutical Quality Control: A Guide to CDMO Selection & Outsourcing, provides a practical framework for evaluating quality and testing capabilities.
Firelli Alonso also emphasizes the value of seeing a facility first hand rather than relying exclusively on virtual assessments:
“You have to go to the facility and check it out. I like to talk to the workers, the operators themselves, because the management is going to paint a nice picture, right? But if you talk to the operators and visit the facility, you can have a good sense, is this genuine?”– Firelli Alonso, former Senior Director of External Manufacturing, Pfizer
Full interview: Quality, Integration, and Culture: Key Lessons in CDMO Selection from Firelli Alonso, PharmaSource Podcast.
For External Quality, the lesson is simple: the quality system on paper and the quality culture on the manufacturing floor are not necessarily the same thing.
2. Risk Based Quality Due Diligence
Not every CDMO requires the same oversight. A small analytical supplier handling a low risk activity should not receive the same governance model as a strategic commercial partner responsible for a critical biologic. External Quality needs a risk based approach, weighing product criticality, patient impact, process maturity, regulatory requirements, site history, supplier performance, and quality system maturity.
The objective is not maximum oversight. The objective is appropriate oversight.
PharmaSource’s Quality as a Catalyst: How Risk Culture and Transparency Drive CDMO Success explores this with perspectives from Stefan Bouckaert of Johnson & Johnson and Gwladys Mabonzo of MSD.
“Multi factors are coming in, there’s performance metrics coming in.”–Stefan Bouckaert, Vice President, External Supply Integration Quality, Johnson & Johnson
Quality risk should be assessed dynamically, not through a static exercise carried out once and filed away.
Figure 1. Five Dimensions of External Quality Assessment
3. Quality Agreements
Quality agreements establish the operational boundaries between sponsor and CDMO, defining responsibilities for deviations, investigations, CAPA, change control, complaints, batch release, data integrity, audit rights, and escalation procedures.
But the agreement itself is only part of the solution. The real question is whether both organizations operate according to those responsibilities in practice. In CDMO Quality Oversight: How FDA and Pharma Leaders Are Rethinking Data, AI, and Culture, quality leaders explore the tension between data access, confidentiality, and effective oversight.
Denyse Baker, AVP Global Quality External Engagement at Eli Lilly and a former FDA official, explains that sponsors increasingly want visibility into more than their own batch data:
“Everybody wants their own data, but from a quality system standpoint, I would also like to see the overall health of the quality system. How does the CDMO share that without compromising their agreements to keep things proprietary across the different companies?”–Denyse Baker, AVP Global Quality External Engagement, Eli Lilly
Colin Baker, Senior VP Quality Assurance at Bimeda, sits on both sides of that exchange, overseeing a multi region network of CMOs while also serving as a CMO for other companies’ products. He is candid about the risk of opening up systems:
“I’d be hesitant to turn over access to any of our systems. You may need to tie it more closely into your quality agreements so you can be more confident about how the data is used and how it’s stored. I think you’d need to develop frameworks surrounding it specifically.”– Colin Baker, Senior VP Quality Assurance, Bimeda
That tension, between visibility and confidentiality, is becoming one of the defining questions in external quality data sharing, and quality agreements are the natural place to resolve it.
4. Ongoing Quality Oversight
Qualification is only the beginning. Once approved, External Quality must keep assessing the partner, monitoring deviation trends, CAPA aging, change control cycle time, batch failures, complaints, right first time performance, and inspection findings.
But metrics should never substitute for judgment. A site can meet every KPI while still developing deeper quality problems.
“You can design all the quality systems you want, but without the right culture, it’s going to mean nothing, because the decisions get made based on the values of the organization, not based on the systems.”–Jeff Broadfoot, VP Quality Operations, Emergent
The function needs to assess not only whether the system exists, but how people behave when it is tested.
Quality Metrics: What Should External Quality Measure?
There is no single universal set of External Quality KPIs, but a useful scorecard typically combines leading and lagging indicators.
Lagging indicators show what has already happened: number of deviations, major and critical deviations, batch failures, OOS events, complaints, audit findings, regulatory observations, CAPA failures, recurring investigations, and product-quality incidents.
Leading indicators may provide earlier signals of deterioration: increasing deviation complexity, CAPA aging, repeat deviations, a growing change-control backlog, increasing employee turnover, recurring audit observations, reduced management engagement, increasing cycle times, delayed responses, deteriorating transparency, and reduced access to operational information.
The second group matters because effective External Quality should not simply document failures after they happen — it should help identify where failures are becoming more likely. In the CDMO Quality Oversight discussion, Jeff Broadfoot describes how AI and long-term trending can help identify patterns earlier:
“We’ve been starting to use AI to look at long-term trends, so that we catch a trend earlier and we can do something about it earlier, before it becomes a problem.”— Jeff Broadfoot, VP Quality Operations, Emergent
That represents an important shift, from reactive oversight to predictive quality management.
Quality Culture Matters as Much as the Quality System
One of the strongest themes in PharmaSource’s quality coverage is that quality culture cannot be separated from quality performance.
Liesbeth Foesters, Vice President and Head of External and Clinical Supply Quality at UCB, describes the difference between simply following procedures and making quality-conscious decisions:
“I’m really talking about making sure you’re doing the right thing at the right moment.”— Liesbeth Foesters, Vice President and Head of External and Clinical Supply Quality, UCB
Transparency Is a Quality Capability
A partner that communicates problems early gives the sponsor more options. A partner that delays or obscures problems reduces the sponsor’s ability to respond.
“The more transparent you are with your customer, the less they are going to worry. The less you are transparent, the more scrutiny you are going to create.”– Gwladys Mabonzo, Associate Director, External Manufacturing Vaccines, MSD
External Quality should treat transparency as an indicator of maturity. Does the CDMO escalate problems early? Does management acknowledge weaknesses without becoming defensive?
External Quality Should Challenge the CDMO
An effective function should not simply confirm a CDMO has met requirements. It needs the credibility to challenge partners, because agreement does not equal quality.
“And I would not choose a CMO that will just agree. I would pick a CMO that challenges you, with facts.”– Isabel Feuerstein, Head of Business Development for EU and Asia CMO, Novartis
Full interview: Novartis on What Great CDMO Partnerships Actually Look Like, PharmaSource Podcast.
A strong partner should be willing to flag risk or push back on a proposed approach. The goal is not confrontation. It is constructive challenge based on evidence.
External Quality Is Becoming More Data Driven
As networks grow, it becomes harder to manage quality through periodic meetings and spreadsheets alone. But technology does not automatically create better quality.
Colin Baker of Bimeda describes the shift he sees as most important in external quality management, moving from responding to problems to anticipating them:
“You can’t be reactive. You have to be able to look at it in a way where you can start to anticipate where the trends are going, versus just waiting until something happens and then reacting to it. If you can find a partner where they do have electronic data and they’ll give you access into it, it can be a very powerful tool because then you can work directly with them, you can give them information to say, here’s what you might want to consider.”– Colin Baker, Senior VP Quality Assurance, Bimeda
In PharmaSource’s Podcast: How Takeda Drives Quality Excellence Across External Manufacturing Networks, Ingrid Lux of Takeda discusses creating practical mechanisms for real time information sharing, a joint “safe space” that lets information flow while respecting both sides.
Digital quality is about better visibility and decision making, not technology for its own sake.
The Regulatory Dimension of External Quality
Regulators increasingly expect companies to understand and control activities performed by external partners. PharmaSource’s analysis, Regulatory Violations Are the #1 Reason CDMOs Lose Bids, examines how quality oversight can break down across outsourced relationships.
Compliance is the baseline, not the complete definition of quality maturity.
Eric Twum, Regulatory Specialist in the Office of Quality Surveillance at FDA’s Office of Pharmaceutical Quality, brings the regulator’s view to this question. Through CDER’s Quality Management Maturity program, the agency is building a framework that assesses the behaviors and practices behind an establishment’s quality culture, explicitly beyond CGMP compliance, across five areas: management commitment to quality, business continuity, advanced pharmaceutical quality systems, technical excellence, and employee engagement and empowerment.
The stakes are supply security. FDA data shows quality issues and manufacturing delays accounted for 42 percent of new drug shortages between 2022 and 2024, and the program was designed to help a market that has historically struggled to recognize or reward mature quality systems. For External Quality teams, this points to a wider trend: maturity assessment is moving beyond a sponsor’s internal judgment call and toward a more structured, comparable framework that CDMOs will increasingly be measured against.
External Quality and Technology Transfer
A process that performs successfully at one site may behave differently when transferred to another because of differences in equipment, scale, raw materials, and operators.
External Quality should be involved alongside Technical Operations, CMC, and the CDMO throughout the transfer. PharmaSource’s Tech Transfer, RFx, and Quality Oversight: 19 Outsourcing Excellence Takeaways brings together lessons on integrating quality into the outsourcing process from the start, rather than as a final approval step.
From Quality Oversight to Quality Partnership
The most mature External Quality organizations are moving beyond traditional supplier oversight. The objective is a relationship in which both sides share information, identify risks early, and work together.
“What is for me very essential is a culture. You sense it really working with some of the companies.”–Stefan Bouckaert, Vice President, External Supply Integration Quality, Johnson & Johnson
A strategic relationship is not static. Volumes increase, requirements change, and new technologies get introduced. The quality relationship needs to evolve alongside it.
Figure 3. From Oversight to Partnership
PharmaSource’s Novartis on What Great CDMO Partnerships Actually Look Like offers another angle. Isabel Feuerstein highlights culture, transparency, and a willingness to challenge the client. Her colleague Mark Schiefermeier adds a useful test: ask CDMOs about their problems, rather than accepting a picture in which everything appears perfect.
What Should an External Quality Team Look for in a CDMO?
A practical assessment considers five dimensions:
- Quality system maturity. Is the system robust? Are CAPAs sustainable?
- Regulatory track record. What inspections has the site undergone? Are there recurring findings?
- Quality culture. Does management visibly prioritize quality? Does the site learn from mistakes?
- Transparency. Are problems escalated early? Is information presented accurately?
- Partnership capability. Can the CDMO challenge the sponsor constructively? Can it adapt as requirements change?
External Quality Checklist
Before selecting or renewing a strategic CDMO relationship, External Quality teams should be able to answer the questions below.
Figure 4. External Quality Checklist
The Future of External Quality
External Quality is becoming a more strategic discipline. As companies outsource more manufacturing and manage increasingly complex networks, the function will need to combine traditional quality expertise with stronger capabilities in data, risk management, governance, and influence.
The future External Quality leader will need to interpret manufacturing data, assess organizational culture, challenge technical decisions, manage risk across networks, and influence organizations over which they have no direct authority.
This is why External Quality should not be viewed simply as an extension of supplier auditing. It is a strategic capability for managing pharmaceutical manufacturing risk.
The strongest External Quality organizations will not necessarily be the ones that conduct the most audits. They will be the ones that develop enough visibility, influence, and trust to know where intervention is needed, and when a partner is capable of managing quality independently.
As the industry moves toward deeper CDMO partnerships, External Quality will increasingly determine whether those partnerships deliver not only compliant manufacturing, but reliable, resilient, and sustainable supply.
Related PharmaSource Resources
- Quality, Integration, and Culture: Key Lessons in CDMO Selection from Firelli Alonso
- Quality as a Catalyst: How Risk Culture and Transparency Drive CDMO Success
- CDMO Quality Oversight: How FDA and Pharma Leaders Are Rethinking Data, AI, and Culture
- Regulatory Violations Are the #1 Reason CDMOs Lose Bids
- How Takeda Drives Quality Excellence Across External Manufacturing Networks
- Novartis on What Great CDMO Partnerships Actually Look Like
- Tech Transfer, RFx, and Quality Oversight: 19 Outsourcing Excellence Takeaways
- Pharmaceutical Quality Control: A Guide to CDMO Selection & Outsourcing
- Outsourcing Oversight Plan Template
Together, these resources point to a single underlying idea: quality is not something to inspect after a CDMO has been selected. It is something that needs to be designed into the relationship from the beginning.